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Summary  Patients  with  pulmonary  hypertension  must  be  evaluated  using  a  multimodality
approach  to  ensure  a  correct  diagnosis  and  basal  evaluation  as  well  as  a  prognostic  assessment.
Beyond the  assessment  of  pulmonary  pressures,  the  echocardiographical  examination  allows  the
evaluation  of  right  ventricular  adaptation  to  elevated  afterload.  Numbers  of  variables  are  com-
monly used  in  the  assessment  of  the  pulmonary  hypertension  patient  in  order  to  detect  changes
in right  heart  geometry,  right-to-left  interaction  and  right  ventricular  dysfunction.  Whereas  an
isolated change  in  one  echocardiographical  variable  is  not  meaningful,  multiple  echocardio-
graphical variable  modiﬁcations  together  provide  accurate  information.  In  this  review,  we  will
link pulmonary  hypertension  pathophysiological  changes  with  echocardiographical  indices  and
describe  the  clinical  implications  of  echocardiographical  ﬁndings.
© 2014  Elsevier  Masson  SAS.  All  rights  reserved.
Abbreviations: 2D, Two-dimensional; 3D, Three-dimensional; dPAP, Diastolic pulmonary artery pressure; IVA, Isovolumic acceleration;
IVCc, Isovolumic contraction velocity; LV, Left ventricle/ventricular; LVOT, Left ventricular outﬂow tract; mPAP, Mean pulmonary artery
pressure; MPI, Myocardial performance index; PA, Pulmonary artery; PAH, Pulmonary arterial hypertension; PAP, Pulmonary artery pressure;
PR, Pulmonary regurgitation; RA, Right atrium/atrial; RAP, Right arterial pressure; RV, Right ventricle/ventricular; sPAP, Systolic pulmonary
artery pressure; TAPSE, Tricuspid annular plane systolic excursion; TR, Tricuspid regurgitation; VTI, Velocity-time integral.
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Résumé  L’imagerie  cardiaque  multi-modalité  est  indispensable  à  l’évaluation  diagnostique  et
pronostique des  patients  atteints  d’hypertension  pulmonaire.  Bien  plus  que  la  mesure  des  pres-
sions pulmonaires,  l’échocardiographie  permet  l’évaluation  de  la  fonction  ventriculaire  droite
traduisant  l’adaptation  du  cœur  droit  à  l’élévation  des  résistances  pulmonaires.  Alors  que  la
modiﬁcation  isolée  d’une  variable  échographique  n’est  que  peu  informative,  celle  de  plusieurs
paramètres  échographiques  est  plus  souvent  pertinente.  Dans  cette  revue,  nous  décrivons
les modiﬁcations  physiopathologiques  du  cœur  droit  et  du  couple  VD-AP  dans  l’hypertension
pulmonaire  par  l’approche  échographique  et  soulignons  l’intérêt  clinique  de  ces  différents
paramètres  échocardiographiques.
© 2014  Elsevier  Masson  SAS.  Tous  droits  réservés.
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Rackground
ulmonary  hypertension  is  a  progressive  and  severe
ulmonary,  vascular  and  cardiac  disorder.  Pulmonary  hyper-
ension  is  deﬁned  by  an  increase  in  mean  pulmonary  artery
ressure  (mPAP)  to  ≥25  mmHg  at  rest  as  determined  by
ight  heart  catheterization,  the  ‘gold  standard’  [1].  Usually,
atients  are  screened  with  echocardiography  (Table  1),  and
ight  heart  catheterization  allows  measurement  of  cardiac
utput  and  differentiation  between  pre-  and  postcapillary
ulmonary  hypertension.  Pulmonary  hypertension  can  be
ivided  into  subsets  sharing  similar  underlying  pathophys-
ology,  detailed  in  Fig.  1  [2].
Although  the  degree  of  pulmonary  hypertension  charac-
erizes  this  condition,  it  does  not  correlate  with  symptoms
r  survival.  Right  ventricular  (RV)  physiology  (RV  mass  and
unction)  is  closely  related  to  functional  class,  exercise
apacity  and  survival  [3,4].  Advanced  therapies,  which
im  to  decrease  pulmonary  vascular  resistance,  usually
igniﬁcantly  improve  RV  function,  but  the  observed  decrease
n  mPAP  is  only  moderate.
Table  1  Echocardiographical  screening  for  patients  at
risk  of  pulmonary  hypertension.
TR  Vmax
≤2.8  m/s  +  echocardiographical
risk  factors
PH possible
2.9—3.4  m/s  PH  possible
>3.4  m/s  PH  likely
Echocardiographical  risk  factors  suggesting  pulmonary
hypertension
Dilated  right  ventricle/right
atrium
Increased  PR  velocity
Pulmonary  acceleration  time
<105  ms
TAPSE  <20  mm
‘D-shaped’  interventricular
septum
PH: pulmonary hypertension; PR: pulmonary regurgitation;
TAPSE: tricuspid annular plane systolic excursion; TE: tricuspid
regurgitation.
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aIn  clinical  practice,  ultrasound  is  by  far  the  most  common
V  imaging  modality,  especially  in  the  setting  of  pulmonary
rterial  hypertension  (PAH).  Transthoracic  echocardiogra-
hy  provides  a  number  of  variables  for  evaluating  right
eart  haemodynamics  (Table  2).  It  is  critical  to  recognize
arly  signs  of  PAH  with  echocardiography  in  order  to  reduce
he  delay  between  ﬁrst  symptoms  and  time  of  diagno-
is.  Echocardiography  is  particularly  suitable  in  pulmonary
ypertension  studies  as  it  is  non-invasive,  cost-effective  and
idely  available.
Thus,  the  aim  of  this  paper  is  to  describe  the  car-
iac  alterations  related  to  pulmonary  hypertension,  and  to
eview  and  discuss  the  extent  to  which  echocardiography
lays  a  key  role  in  early  diagnosis  and  prognosis  in  pulmonary
ypertension.
ight ventricular anatomy and
athophysiology
he  right  ventricle  (RV)  is  the  most  anterior  chamber  of  the
eart  and  can  be  divided  into  three  chambers:  the  inlet,
he  apex  and  the  infundibulum.  In  comparison  with  the  left
entricle  (LV),  the  RV  is  characterized  by  prominent  tra-
eculations  that  limit  the  accuracy  of  contour  tracing  to
elineate  the  endocardial  border.  A  complex  shape,  opposite
o  the  ellipsoidal  shape  of  the  LV,  also  characterizes  the  RV
5].  When  viewed  in  cross  section,  the  RV  is  crescent  shaped,
hereas  it  appears  triangular  when  viewed  longitudinally  or
rom  the  side.  However,  the  RV  shape  is  inﬂuenced  by  RV-LV
nteractions,  depending  on  the  position  of  the  interventric-
lar  septum.  In  normal  conditions,  the  RV  volume  is  larger
han  the  left  ventricular  (LV)  volume,  whereas  the  RV  mass
epresents  approximately  only  one  ﬁfth  of  the  LV  mass  [6].
he  myoﬁbre  arrangement  is  also  particular,  in  that  almost
nly  two  muscle  layers  compose  the  RV  wall:  the  superﬁcial
ayer  (circumferential)  and  the  deep  layer  (longitudinally
rranged),  thus  explaining  in  normal  RVs  the  predominance
f  longitudinal  contraction,  with  no  intermediate  circumfer-
ntial  layer.
Regarding  RV  contraction  physiology,  three  individual
omponents  lead  to  normal  contraction:  the  inward  motion
f  the  free  wall;  longitudinal  shortening;  and  the  traction
f  the  free  wall,  secondary  to  LV  contraction  [7].  In  conse-
uence,  RV  contraction  relies  mostly  on  LV-RV  interaction
nd  longitudinal  deformation.
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1 Pulmonary arterial hypertension
1.1 Idiopathic
1.2 Heritable (BMPR2;  ALK1, ENG and others)
1.3 Drug and toxin induced
1.4 Associated pulmonary arterial hypertension
1.4.1 Connective tissue disease
1.4.2 HIV infection
1.4.3 Portal hypertension
1.4.4 Congenital heart disease (CHD-PAH)
1.4.5 Schistosomiasis
1.4.6 Chronic haemolytic anaemia
1 Pulmonary veno-occlusive disease and/or capillary haemangiomatosis
1’’ Persistent pulmonary hypertension of the newborn
2 Pulmonary hypertension due to left heart disease
3 Pulmonary hypertension due to lung diseases and/or hypoxia
4 Chronic thromboembolic pulmonary hypertension
5 Pulmonary hypertension with unclear multifactorial mechanisms
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Right ventricle/pulmonary artery coupling
Under  normal  circumstances,  the  pulmonary  circulation
unit  has  lower  vascular  resistance  and  greater  distensi-
bility  than  the  systemic  circulation.  There  is  a  complex
relationship  between  RV  systolic  function,  preload  and
afterload.  The  RV  has  a  heightened  sensitivity  to  afterload
elevation  [8,9]  (i.e.  mainly  increased  pulmonary  vascu-
lar  resistance).  Preservation  of  RV-pulmonary  artery  (PA)
coupling  is  critical  for  the  maintenance  of  RV  function:
PAs  facilitate  the  transition  from  an  RV  pulsed  ﬂow  to
an  almost  continuous  ﬂow  at  the  capillary  levels.  Under
pathological  conditions,  increased  PA  stiffness  leads  to
higher  pulsatile  RV  work  and  promotes  RV  dysfunction.
Resistances  in  the  small  vessels  mainly  represent  pul-
monary  vascular  resistance.  With  regard  to  this  deﬁnition,
pulmonary  vascular  capacitance  is  a  measure  of  global
workload  of  the  RV,  accounting  for  large  vessels  and  pul-
satile  elements.  A  high-capacitance  allows  the  forward
pulmonary  blood  to  be  ‘stored’  in  the  capacitant  vessels
and  decreases  the  RV  load.  The  RV  evolution  from  compen-
sated  to  decompensated  follows  changes  in  the  pulmonary
vascular  bed:  from  a  normal  high-capacitance  state  to
t
e
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t13) updated classiﬁcation of pulmonary hypertension.
rterial  vasoconstriction  and  proliferative  obstructive  vas-
ular  remodelling.
The  RV  adapts  better  to  volume  overload  than  to  pres-
ure  overload.  Different  types  of  overload  result  in  different
ypes  of  RV  adaptation.  For  example,  experimental  PA  band-
ng  (pressure  overload)  leads  to  RV  hypertrophy,  mild  RV
ilatation  and  reduced  exercise  capacity  with  calcineurin
ctivation,  whereas  volume  loading  (shunt)  leads  to  hyper-
rophy  and  severe  RV  dilatation  with  preserved  exercise
apacity  [10].  Echocardiography  is  helpful  for  distinguish-
ng  volume  overload  with  increased  pulmonary  pressures
ut  normal  pulmonary  vascular  resistances  from  normal  (or
educed)  ﬂow  elevated  PA  pressures  and  pulmonary  vascular
esistances  (PAH).  It  is  crucial  to  differentiate  between  these
resentations,  especially  in  atrial  septal  defect  patients,  in
rder  to  determine  the  need  for  defect  closure  or  pulmonary
asodilators.
RV  adaptation  to  increased  pressure  overload  in  pul-
onary  hypertension  depends  on  the  overload  severity  andhe  rapid  onset  of  the  disease;  this  suggests  that  RV  remod-
lling  has  an  important  role  in  protecting  against  pulmonary
ypertension  (as  in  congenital  PAH).  RV  myocardial  hyper-
rophy  is  the  ﬁrst  adaptative  remodelling  response.  Changes
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Table  2  Most  validated  and  useful  variables  in  the  routine  evaluation  of  pulmonary  hypertension  patients.
Clinical  situation  Echocardiographical  variables  Clinical  relevance
Diagnosis  TR  Vmax RV-RA
gradient—estimation  of
sPAP  (4  ×  Vmax2 +  RAP)
Vmax >  2.8  m/s
sPAP  >  35  mmHg
PR  Vmax mPAP  =  4  ×  Vmax2 +  RAP  mPAP  ≥  25  mmHg
Telediastolic  PR  velocity dPAP  =  4  ×  velocity2 +  RAP  sPAP  =  3  mPAP—2  dPAP
Pulmonary  acceleration  time <93  ms
TAPSE Systolic  dysfunction <18  mm
S’  Predictor  of
sPAP  > 40  mmHg
<12 cm/s
RV  diameter  (D1)  >40—42  mm
3D  RV  end-diastolic  volume  >89  mL/m2
RV  wall  thickness  RA  pressure  >5  mm
RA  area  >18  cm2
IVC  diameter  and  compliance  >21  mm
Aetiological  approach  Intra-  or  extracardiac  shunt  Contrast  TTE  sometimes
useful  (TOE  if  necessary)
Congenital  PAH
TR  Vmax/pulmonary  VTI  Increased  pulmonary
vascular  resistance
>0.2
E/E’m  LV  ﬁlling  pressures  >10  (group  2  patients)
PA  thrombosis  Group  4  patients?  (or
pulmonary  hypertension
complicated  by  PA
thrombosis)
Prognosis  TAPSE  <16  mm
S’  <10  cm/s
RV  fractional  area  change  <35%
Peak  longitudinal  RV  strain  ≥19%
IVCv  <9  cm/s
Tei  index  (PW)  >0.4
Main  PA  diameter  >29  mm
LV  eccentricity  index  >1.4
Pericardial  effusion  Presence
Follow-up  RV  diameter  Improves  with  advanced
therapy
RV  fractional  area  change
Tei  index
Mitral  E/A  and  E/E’
IVC: inferior vena cava; IVCv: isovolumetric contraction velocity; LV: left ventricle; mPAP: mean pulmonary artery pressure; PA: pul-
monary artery; PAH: pulmonary arterial hypertension; PAP: pulmonary artery pressure; PR: pulmonary regurgitation; PW: pulsed-wave;
RA: right atrial; RAP: right atrial pressure; RV: right ventricle; sPAP: systolic pulmonary artery pressure; TAPSE: tricuspid annular plane
systolic excursion; TOE: transoesophageal echocardiography; TTE: transthoracic echocardiography; TR; tricuspid regurgitation.
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mn  sarcomeric  protein  expression  and  renin-angiotensin  sys-
em  activation  promote  RV  myocardial  ischaemia,  whereas
ilatation  occurs  subsequently.  The  increased  preload  ini-
ially  compensates  for  the  reduced  contractility,  to  maintain
he  stroke  volume.  The  RV  becomes  more  spherical  due  to
he  increased  RV  volume,  compressing  the  LV  and  causing
iastolic  dysfunction.  With  chronic  pressure  overload,  right
trial  (RA)  contractility  and  distensibility  increase  [11]  until
A  pressure  increases.  Progressively,  as  the  RV  dilates,  the
lling  pressures  increase,  leading  ultimately  to  RV  failure.
he  intensity  of  the  neurohormonal  activation  contributes
o  RV  adverse  remodelling  and  failure.  The  presence  of
T
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eunctional  tricuspid  regurgitation  (TR),  caused  by  RV/RA
ilatation,  also  contributes  to  the  reduced  cardiac  output.
ssessment of pulmonary artery pressures
tandard  Doppler  echocardiography  provides  a reliable  esti-
ation  of  PAP:  in  the  absence  of  pulmonary  ﬂow  obstruction,
R  peak  velocity  and  pulmonary  valve  acceleration  time  are
orrelated  with  systolic  PAP  (sPAP)  and  mPAP,  respectively,  as
ssessed  by  right  heart  catheterization.  sPAP  is  considered
qual  to  RV  systolic  pressure  in  the  absence  of  pulmonary
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iImaging  in  pulmonary  hypertension:  Focus  on  the  role  of  ech
valve  stenosis  or  outﬂow  tract  obstruction.  RV  systolic  pres-
sure  can  be  determined  by  the  addition  of  RA  pressure  (RAP)
to  the  pressure  gradient  between  the  right  chambers,  cal-
culated  using  the  modiﬁed  Bernoulli  equation:  P  =  4  ×  TR
Vmax2.  European  guidelines  [12]  consider  the  echocardio-
graphical  diagnosis  of  pulmonary  hypertension  ‘likely’  when
TR  Vmax is  >3.4  m/s  and  ‘possible’  when  TR  Vmax is  between
2.9  and  3.4  m/s  or  when  TR  Vmax is  ≤2.8  m/s  with  addi-
tional  variables  suggestive  of  pulmonary  hypertension  (RV
dilatation,  hypertrophy  or  increased  pulmonary  regurgitant
velocity).  To  improve  the  accuracy  of  echocardiography  and
limit  the  angle  dependency,  the  TR  jet  should  be  appreci-
ated  from  multiple  RV  views.  However,  in  severe  TR  with
laminar  ﬂow,  the  peak  velocity  does  not  reﬂect  the  RV-RA
pressure  gradient  because  of  early  equalization  of  RV  and
RA  pressures.  In  the  latter,  peak  early  diastolic  and  end-
diastolic  velocities  obtained  from  pulmonary  regurgitation
(PR)  ﬂow  can  provide  an  estimation  of  mPAP  and  diastolic
PAP  (dPAP).
When  present,  PR  is  characterized  by  a  rapid  rise  in  ﬂow
velocity  after  the  valve  closure  and  a  gradual  deceleration
until  the  next  opening.  Peak  PR  velocity  can  estimate  the
mPAP  using  the  equation  mPAP  =  4  ×  PR  Vmax2 +  RAP,  whereas
end-diastolic  PR  enables  the  calculation  of  dPAP  using  the
equation  dPAP  =  4  ×  end-diastolic  PR  velocity2 +  RAP.
Exercise-induced  pulmonary  hypertension  is  an  early
phase  of  the  disease  [13].  However,  as  age  is  an  important
confounding  factor  for  the  elevation  of  PAP  with  exercise,
stress  echocardiography  is  not  recommended,  even  in  high-
risk  patients.  On  the  other  hand,  in  patients  with  established
elevated  sPAP,  elevation  of  PAP  with  exercise  can  be  used  as
a  surrogate  for  RV  contractile  reserve;  a  recent  study  has
demonstrated  the  prognostic  value  of  this  variable  in  PAH
patients  [14].
Imaging the right ventricle
Right ventricular linear dimensions
Measurement  of  the  dimensions  of  the  RV  is  an  important
part  of  echocardiography,  as  they  describe  RV  remodelling.
RV  free  wall  thickness  reﬂects  the  degree  of  RV  hypertrophy;
it  should  be  measured  at  the  end  of  diastole  in  subcostal  or
parasternal  long-axis  view,  preferably  at  the  level  of  the  tip
of  the  anterior  tricuspid  leaﬂet.  The  normal  cut-off  for  RV
wall  thickness,  excluding  trabeculations  and  papillary  mus-
cle,  is  5  mm.  As  there  may  be  beneﬁcial  and  detrimental  RV
hypertrophy  regarding  different  metabolic  pathways  [15],
RV  wall  thickening  is  not  independently  associated  with  sur-
vival  in  pulmonary  hypertension.
As  the  RV  dilates  in  response  to  RV  failure  and  increased
pressure  overload,  RV  enlargement  is  a  predictor  of  mor-
tality  in  patients  with  pulmonary  disease  and  pulmonary
hypertension  [16,17].  RV  dimensions  should  be  measured  at
the  basal  mid-cavity  level  as  well  as  longitudinally  using  the
four-chamber  view.  The  basal  diameter  (RV  D1,  upper  limit
42  mm;  Fig.  2A)  should  also  be  compared  with  LV  dimen-
sions,  to  help  to  distinguish  enlarged  RV  from  global  heart
dilatation.  One  major  limitation  of  this  two-dimensional
(2D)  technique  is  that  it  is  highly  dependent  on  the  probe
and  patient  position.  Beyond  RV  dilatation,  PA  dilatation  is
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mportant  to  detect  because  of  its  prognostic  importance
18].
ight ventricular three-dimensional
ssessment
omplex  anatomy  is  usually  best  assessed  using  a  three-
imensional  (3D)  technique.  Three-dimensional  echocardio-
raphy  can  be  used  to  assess  RV  volumes  and  ejection
raction;  it  leads  to  less  underestimation  of  volumes  and
mproved  variability  compared  with  2D-echocardiography
nd  provides  an  accurate  and  reproducible  RV  ejection  frac-
ion  that  could  help  with  serial  measurements.  The  lower
ut-off  for  3D  RV  ejection  fraction  is  44%  and  3D  echocar-
iography  correlates  well  with  cardiac  magnetic  resonance
n  children  [19]  and  adults  [20,21]. The  upper  reference  lim-
ts  for  3D-indexed  RV  end-diastolic  and  end-systolic  volumes
re  89  mL/m2 and  45  mL/m2, respectively.
ricuspid regurgitation
n  PAH,  TR  occurs  as  the  result  of  the  effect  of  increased
V  afterload  on  RV  dilatation  and  function.  TR  is  usually
aused  by  tricuspid  annular  dilatation,  altered  RV  geome-
ry  and  apical  displacement  of  tricuspid  leaﬂets,  failing  to
dapt.  Moderate  or  greater  degrees  of  TR  are  commonly
een  in  advanced  pulmonary  hypertension  [22],  the  sever-
ty  of  TR  being  correlated  with  functional  capacity.  TR  also
ontributes  to  reduced  cardiac  output.
ight ventricular fractional area change
V  fractional  area  change,  deﬁned  as  (end-diastolic
rea  —  end-systolic  area)/end-diastolic  area  ×  100  (Fig.  2A),
s  a  simple  2D  way  to  assess  RV  systolic  function  using  the
pical  four-chamber  view.  Despite  the  limitations  inherent
o  the  method  (difﬁcult  contour  tracing,  foreshortened  api-
al  view  because  of  RV  dilatation),  it  has  been  correlated
ith  cardiac  magnetic  resonance  data  [23]  and  is  considered
s  the  gold  standard  in  RV  assessment.  A  RV  fractional  area
hange  of  <35%  indicates  RV  systolic  dysfunction  and  changes
n  time  correlate  with  clinical  deterioration  [24].  However,
he  signiﬁcant  variability,  when  measured  by  echocardio-
raphy  and  compared  with  cardiac  magnetic  resonance,
xplains  why  it  requires  multiple  measurements.
ongitudinal right ventricular function
ongitudinal  systolic  RV  function  can  be  estimated  using  tri-
uspid  annular  plane  systolic  excursion  (TAPSE)  and  S’  (also
alled  tricuspid  valve  Sm).  TAPSE  (Fig.  2B)  is  one  of  the  sim-
lest  measurements,  an  M-mode  measure  obtained  from  the
pical  view,  which  is  of  critical  importance.  Beyond  reﬂect-
ng  longitudinal  function,  TAPSE  also  correlates  with  global
ndices  of  RV  global  function  [25—27]. RV  dysfunction  is
onsidered  for  TAPSE  <  16  mm.  TAPSE  has  signiﬁcant  prog-
ostic  importance  in  PAH  [28],  especially  in  patients  with
diopathic  PAH,  systemic  sclerosis-associated  PAH  [29]  and
isenmenger’s  syndrome  [30].  However,  TAPSE  is  angle  and
perator  dependent  and  varies  according  to  heart  motion
the  reference  point  being  located  outside  the  heart)  and
he  severity  of  TR  and  RV-LV  interactions  [31].  Tissue  Doppler
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Figure 2. Assessment of right ventricular function. (A) Apical view focused on the right ventricle (RV) with RV inlet end-diastolic measure-
ment (D1) and end-diastolic area (RV ED area) and end-systolic area (RV ES area) tracing, allowing calculation of RV fractional area change
(RV ED area—RV ES area)/RV ED area. (B) Measurement of TAPSE using the four-chamber view. (C) Example of RV free wall speckle-tracking
study showing a decreased longitudinal strain. (D) Tissue Doppler imaging with pulsed Doppler at the tricuspid lateral annulus; the example
shows the measurement of S’ (tricuspid valve [TV] Sm), the isovolumic contraction peak velocity (IVCv) and acceleration during isovolumic
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maging  can  also  determine  the  peak  systolic  velocity  of  the
ateral  tricuspid  annulus  (by  pulsed  tissue  Doppler  and/or
olour-coded  tissue  Doppler)  (Fig.  2D).  S’  is  well  correlated
ith  TAPSE  and  the  lower  reference  limit  in  normal  control
atients  has  been  established  as  10  cm/s  [32,33].  However,
hese  variables  remain  limited,  given  that,  as  shown  by  a
D  study  [34],  under  pathological  conditions  the  RV  has  dif-
erential  regional  function,  with  distinct  features  for  each
ompartment,  thus  having  a  different  effect  on  the  overall
ystolic  function.
Another  tissue  Doppler  variable  derived  from  the  basal
ree  RV  wall  that  is  useful  in  clinical  practice  is  myocardial
cceleration  during  isovolumic  acceleration  (IVA)  (Fig.  2D)
35].  IVA  is  deﬁned  by  the  peak  isovolumic  myocardial  veloc-
ty  (IVCv)  divided  by  time  to  peak  velocity,  the  zero  crossing
ine  deﬁning  the  onset  of  myocardial  acceleration.  IVA  is
ess  load-dependent  than  other  indices  [36],  but  is  fre-
uency  dependent,  explaining  why  it  should  be  indexed  to
he  heart  rate  (divided  by
√
RR [ms]).  The  lower  reference
imit  by  pulsed-wave  tissue  Doppler  imaging  is  2.2  m/s2.
espite  being  a  reliable  indicator  of  RV  function  [37],  IVA
as  not  yet  been  related  to  prognosis  in  patients  with  PAH;
owever,  IVCv  (peak  velocity)  has  been  identiﬁed  recently
s  an  independent  predictor  of  clinical  outcomes  in  group  1
ulmonary  hypertension  patients  [38].
t
R
s
Dher than VTI].
ight ventricular adaptation
he  RV  myocardial  performance  index  (MPI)  or  Tei  index  [39]
Fig.  3A),  deﬁned  by  the  ratio  of  isovolumic  time  divided
y  ejection  time,  reﬂects  the  global  RV  performance  and
daptation.  It  can  be  obtained  either  by  pulsed  Doppler  on
V  outﬂow  and  the  tricuspid  valve  (using  similar  RR  inter-
als)  or  by  tissue  Doppler  imaging.  Reference  values  differ
etween  these  two  methods  [40]  (upper  reference  limits
.40  [pulsed  Doppler]  and  0.55  [tissue  Doppler]).  This  index
s  related  to  prognosis  in  PAH  and  is  associated  with  clinical
mprovement  following  advanced  therapies  [41].  In  chronic
hromboembolic  pulmonary  hypertension,  RV  MPI  is  corre-
ated  with  disease  severity  and  associated  with  outcomes
42]. RV  MPI  has  also  been  validated  in  paediatric  pulmonary
ypertension,  MPI  being  correlated  with  mPAP  and  response
o  therapy  [43].  The  measure  of  total  isovolumic  time  pro-
ides  with  the  same  indications  than  MPI;  it  has  been  related
o  outcomes  in  Eisenmenger’s  syndrome  [30]  and  is  related
verall  to  the  disease  severity  and  degree  of  pulmonary
ypertension  [44,45].  Calculation  of  the  systolic  to  dias-
olic  duration  ratio  (S/D  ratio)  is  another  means  of  assessing
V  adaptation.  Durations  of  systole  and  diastole  are  mea-
ured  from  the  apical  view  (Fig.  3B) to  obtain  the  clearest
oppler  signal  of  TR.  Systolic  duration  is  measured  as  the
Imaging  in  pulmonary  hypertension:  Focus  on  the  role  of  echocardiography  267
Figure 3. Assessment of right ventricular adaptation and right ventricle/left ventricle interaction. (A) Transtricuspid ﬂow recorded with
pulsed Doppler, with measurement of tricuspid valve E (TV E) and ‘Tei a’ (the interval between two transtricuspid ﬂows). (A’) Pulmonary
ﬂow with tracing of velocity-time integral (VTI) and measurement of pulmonary ejection time ‘Tei b’; Tei index (or right ventricular [RV]
myocardial performance index) can be calculated using the formula (a—b)/b. (B) Tricuspid regurgitation (TR) ﬂow in pulmonary hypertension,
with peak velocity 5.2 m/s and an example of the S/D ratio calculation (S = duration of tricuspid regurgitation; D = interval between S and
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ithe next TR ﬂow). (C) Short-axis view with determination of left ve
duration  of  the  TR  ﬂow,  whereas  diastolic  duration  is  consid-
ered  from  termination  to  onset  of  TR.  An  increase  in  the  S/D
ratio  reﬂects  a  certain  degree  of  RV  dysfunction,  with  longer
systole  and  abnormal  cardiac  performance;  it  is  one  of  the
strongest  independent  predictors  of  death  in  a  population
with  Eisenmenger’s  syndrome  and  independently  predicts
lung  transplantation  and  death  in  paediatric  PAH  (cut-off
1.4)  [46].
Speckle-tracking imaging
Speckle-tracking  imaging  can  help  to  identify  the  early  signs
of  RV  dysfunction  and  to  follow  patients  under  therapy.  RV
systolic  longitudinal  strain  is  reduced  in  PAH  (Fig.  2C)  and
probably  accounts  for  the  RV  global  dysfunction,  given  the
ﬁbre  arrangement;  it  also  improves  in  conjunction  with  the
6-minute  walked  distance  in  responders  to  advanced  therapy
[47].  An  RV  longitudinal  strain  <19%  has  been  described  as
an  independent  predictor  of  all-cause  mortality  [48].
One  question  of  critical  importance  in  RV  evaluation  is
whether  or  not  the  ‘RV  dysfunction’  will  normalize  after  a
lung  transplant;  in  other  words,  if  normalizing  RV  afterload
allows  the  full  recovery  of  RV  function.  Most  of  our  indices
are  load-dependent  and  thus  will  change  in  response  to  dif-
ferent  RV  afterloads.  However,  in  routine  practice,  it  can
indeed  be  useful  to  monitor  the  variations  in  load-dependent
t
a
d
dular eccentricity index (>1.4).
ndices  as  it  gives  us  valuable  information  about  the  RV  con-
equence  of  modiﬁed  loading  conditions.
ight atrial function
hree  main  functions  of  the  right  atrium  (RA)  have  been
escribed:  the  reservoir  function  for  the  systemic  venous
eturn;  the  passive  conduit  role  in  early  diastole;  and  the
ctive  conduit  with  atrial  contraction  in  late  diastole  [49].
ubcostal  and  four-chamber  incidences  are  the  main  acous-
ic  windows  for  the  RA  assessment.
RA  surface,  as  estimated  by  planimetry  in  four-chamber
iew  [50], is  a  marker  of  RV  diastolic  dysfunction.  The  upper
imit  for  RA  dilatation  is  18  cm2 [33].  When  the  acoustic
indow  is  not  adequate,  linear  dimensions  can  be  used;
owever,  they  correlate  less  well  with  3D  RA  volume.  The
ntensity  of  RA  dilatation  correlates  with  the  degree  of  PAH
51]  and  is  also  predictive  of  survival  in  idiopathic  PAH  [52]
nd  in  Eisenmenger’s  syndrome  [30].  The  prognostic  role
f  the  RA  area/LA  area  ratio  has  also  been  demonstrated
n  these  patients.  2D  RA  volume  assessment  is  not  rou-
inely  recommended.  In  a  recent  study,  RA  remodelling,  as
ssessed  by  3D  echocardiography,  was  the  most  indepen-
ent  predictive  factor  of  adverse  outcomes  [53], using  RA
ilatation  and  RA  sphericity  index.
2e
m
T
R
c
w
r
1
b
I
i
s
L
D
p
A
u
i
P
r
p
t
p
R
A
s
s
b
l
t
r
n
t
f
T
i
i
i
t
A
c
a
o
g
i
r
P
s
P
P
o
r
g
(
h
(
(
a
f
t
p
a
(
d
d
i
a
c
i
g
e
c
a
c
T
e
h
G
r
i
c
‘
t
t
t
r
a
r
d
t
E
h
ﬁ
i
p
i
o
i
i
m
b
p68  
RAP  can  be  estimated  by  echocardiography  and  reﬂects
levated  RV  ﬁlling  pressures.  RAP  is  most  commonly  esti-
ated  by  IVC  diameter  and  collapsibility  during  a  sniff  test.
he  assessment  is  quite  easy  in  patients  with  low  or  elevated
A  pressure.  When  IVC  diameter  is  <2.1  cm  with  inspiratory
ollapse  >50%,  it  suggests  a  normal  RA  pressure  of  3  mmHg,
hereas  when  the  IVC  diameter  is  >2.1  cm  with  an  inspi-
atory  collapse  <50%,  it  suggests  a  elevated  RA  pressure  of
5  mmHg.  In  intermediate  cases,  a  value  of  8  mmHg  may
e  determined,  but  the  use  of  other  indices  is  preferable.
ndices  of  elevated  RA  pressure  are:  restrictive  tricuspid  ﬁll-
ng  pattern;  tricuspid  E/E’  ratio  >6  [54];  and  hepatic  vein
ystolic  ﬁlling  fraction  <55%.
eft ventricular assessment
ifferentiating pre- from postcapillary
ulmonary  hypertension
s  described  in  multiple  studies,  echocardiography  can  be
sed  to  detect  elevated  LV  ﬁlling  pressures,  distinguish-
ng  PAH  from  pulmonary  venous  hypertension.  Typically,
AH  patients  present  a  mitral  inﬂow  typical  of  impaired
elaxation  [55]  and  E/E’<10,  suggesting  normal  LV  ﬁlling
ressures,  with  a  compressed  and  underﬁlled  LV  [56].  In  con-
rast,  group  2  pulmonary  hypertension  patients  will  usually
resent  with  an  elevated  E/E’  ratio.
ight ventricle/left ventricle relationship
s  the  RV  pressure  overload  progresses,  the  interventricular
eptum  shifts  to  the  left,  compressing  the  LV.  The  normal
hort-axis  view  becomes  distorted  and  the  left  ventricle
ecomes  ‘D-shaped’  with  a  ﬂattening  ventricular  septum,
eading  to  diastolic  dysfunction.  This  can  be  quantiﬁed  by
he  eccentricity  index  (Fig.  3C)  (ratio  of  the  LV  anteroposte-
ior  and  septolateral  dimensions),  the  value  of  which  under
ormal  conditions  is  1.  The  timing  of  the  septal  shift  can  help
o  distinguish  RV  volume  overload  (end-diastolic  shift  only)
rom  pressure  overload  (predominant  end-systolic  shift).
his  index  is  a  strong  predictor  of  outcomes  in  PAH  [52]  and
mproves  with  advanced  therapies  [57].  Speckle-tracking
maging  could  provide  further  insights  into  LV  mechanics
n  PAH  and  recent  studies  have  indicated  that  abnormal  LV
orsion  and  circumferential  strain  are  present  in  PAH  [58].
 signiﬁcant  relationship  between  decreased  LV  strain  and
linical  outcomes  has  also  been  observed  [59].
Cardiac  output  is  also  of  prognostic  importance.  The
ortic  output  can  be  measured  using  this  formula:    ×  LV
utﬂow  tract  (LVOT)  diameter2/4  ×  LVOT  velocity-time  inte-
ral  (VTI)  ×  heart  rate.  This  estimation  correlates  with
nvasive  cardiac  output,  but  remains  relatively  inaccu-
ate  (heart  rhythm  variability,  abnormal  shape  of  LVOT).
ulmonary  VTI  <  12  cm,  TAPSE  <  18  mm  and  S’  <  10  cm/s  are
imple  but  useful  predictors  of  low  cardiac  output  [28].ulmonary artery function
ulmonary  vascular  resistance  is  a  strong  predictor  of
utcomes  in  pulmonary  hypertension;  it  accounts  for  the
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esistance  in  small  vessels.  Estimation  with  echocardio-
raphy  remains  controversial:  dividing  TR  velocity  peak
m/s)  by  pulmonary  VTI  (cm)  allows  differentiation  between
igh  PAP  related  to  high  pulmonary  vascular  resistance
ratio  ≥0.2)  or  to  increased  pulmonary  blood  ﬂow  (<0.2)
e.g.in  atrial  septal  defect  patients)  [60].  However,  a  reli-
ble  estimation  of  pulmonary  vascular  resistance  using  a
ormula  that  includes  this  ratio  (pulmonary  vascular  resis-
ance  =  TR  Vmax/VTI  ×  10  +  0.16)  is  not  valid  in  patients  with
ulmonary  vascular  resistance  >8  Wood  units.
Pulmonary  vascular  capacitance  (accounting  for  medium
nd  large  vessels),  as  assessed  by  echocardiography
stroke  volume  divided  by  pulmonary  pulse  pressure:  [LVOT
iameter2 ×  /4  ×  subaortic  VTI]/[4  ×  ([peak  TR]2—[end-
iastolic  PR]2)]),  is  an  independent  predictor  of  outcomes
n  a  cohort  of  adults  with  PAH  [61].  Estimation  of  PA  compli-
nce,  to  determine  the  pulsatile  nature  of  the  PA  ﬂow,
an  be  obtained  using  colour  M-mode  tissue  Doppler  imag-
ng  on  the  right  PA  (to  measure  diameters)  and  peak  TR
radient  (compliance  [dyne]  =  [PA  systolic—diastolic  diam-
ter]/[diastolic  diameter  ×  systolic  pressure]  ×  104)  and
orrelates  well  with  invasive  measurement  of  compli-
nce  [62]  in  children,  normal  compliance  being  >40%
hange/100  mmHg.
he future of right ventricular
chocardiography in pulmonary
ypertension
iven  its  safety  and  technical  progress,  it  is  likely  that  the
ole  of  echocardiography  in  the  management  of  PAH  will
ncrease  in  the  future.  However,  in  RV  assessment,  espe-
ially  in  PAH,  one  test  should  never  be  considered  as  a
stand  alone’  test.  The  multivariable  approach  should  be
he  rule,  combining  different  echocardiographical  variables
o  obtain  an  ‘RV  performance  score’  or  even  combining
he  results  of  different  examinations  (e.g.  echocardiog-
aphy  and  right  heart  catheterization).  The  multivariable
pproach  has  its  place  in  diagnosis,  an  echocardiographical
ule  accurately  deﬁning  pulmonary  hypertension  haemo-
ynamics  [63],  as  well  as  in  prognosis,  a  score  built  on
he  strongest  echocardiographical  predictors  of  outcomes  in
isenmenger’s  syndrome  allowing  the  identiﬁcation  of  very
igh-risk  patients.  Current  prognosis  equations  would  bene-
t  from  the  incorporation  of  echocardiographical  variables;
t  would  improve  their  predictive  power  and  help  to  identify
atients  who  would  beneﬁt  from  further  speciﬁc  therapies.
Screening  patients  for  possible  pulmonary  hypertension
s  an  important  step  towards  early  diagnosis  and  treatment
f  PAH.  Research  into  early  markers  of  diagnosis  is  of  crit-
cal  importance.  In  this  setting,  exercise  echocardiography
n  conjunction  with  recent  echocardiographical  techniques
ight  allow  important  progress.
In the  near  future,  3D  and  speckle-tracking  imaging  will
e  part  of  the  routine  assessment  of  PAH  patients,  with  sim-
le  technology  becoming  more  accessible;  these  techniques
ill  allow  us  to  gain  insight  into  RV  mechanics  in  pulmonary
ypertension.  3D  RV  volumes  can  be  obtained  directly  by  3D
cquisition  with  a speciﬁc  probe  or,  more  recently,  by  3D
odelling  adapted  from  2D  acquisition  (knowledge-based
oca
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reconstruction)  [64].  However,  further  larger  studies  are
needed  if  this  new  technique  is  to  be  included  as  part  of
our  daily  clinical  practice.
Efforts  are  being  made  in  echocardiography  laboratories
to  maintain  the  best  quality  of  routine  evaluation  exami-
nations  as  well  as  to  homogenize  PAH  echocardiographical
examinations  according  to  American  Society  of  Echocar-
diography/European  Association  of  Cardiovascular  Imaging
guidelines.  This  will  allow  regular  and  accurate  follow-up
of  our  patients  and  prognostic  information  will  come,  not
just  from  one  examination,  but  also  from  the  evolution
of  echocardiographical  variables.  Several  studies  suggest
that  RV  dimensions,  fractional  area  change  [25],  MPI  and
LV  ﬁlling  [57]  improve  over  the  time  with  advanced  ther-
apy.  In  PAH,  stable  or  improved  RV  ejection  fraction  on
serial  assessment  is  associated  with  low  mortality  in  patients
receiving  advanced  therapy  [65].  As  such,  echocardiography
is  a  method  of  choice  for  serial  assessment  of  pulmonary
hypertension  patients.  Furthermore,  the  load-dependency
of  our  RV  function  indices  becomes  an  asset,  allowing  us
to  monitor  with  serial  examinations  RV  function  evolution
related  to  afterload  changes.
Conclusion
Echocardiography  is  a  widely  available,  cost-effective,  safe
and  reliable  examination,  which  provides  us  with  major
diagnostic  and  prognostic  information.  Comparison  of  serial
assessments  allows  monitoring  of  the  efﬁcacy  of  advanced
therapies.  More  recent  ultrasound  techniques,  such  as  3D
echocardiography  and  speckle-tracking,  are  promising;  they
may  provide  additional  data  regarding  RV  and  PA  mechan-
ics  in  pulmonary  hypertension  and  may  allow  the  preclinical
detection  of  high-risk  patients.
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